GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (OTCPK:ROQAF) » Definitions » Total Tax Payable

ROQAF (Roquefort Therapeutics) Total Tax Payable : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Roquefort Therapeutics Total Tax Payable?

Roquefort Therapeutics's Total Tax Payable for the quarter that ended in Jun. 2024 was $0.00 Mil.


Roquefort Therapeutics Total Tax Payable Historical Data

The historical data trend for Roquefort Therapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Total Tax Payable Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Tax Payable
- - -

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Tax Payable Get a 7-Day Free Trial - - - - -

Roquefort Therapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Roquefort Therapeutics Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines